Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
... NKTR ) will announce its financial results ... on Wednesday, February 25, 2009, after the close,of U.S.-based ... will host a conference call to review the results ... (PT). , The press release ...
... VALLEY COTTAGE, N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... Mr.,David Grossman and Mr. Boaz Shweiger have been appointed ... Mr. Grossman will also be assuming,the role of Co-Chief ... of its strategic alternatives. , ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... Researchers at Albany Medical College are releasing results of a ... search for new drug targets aimed at preventing or reversing ... stroke. In the March 5 issue of the ... and his colleagues at the college,s Center for Cardiovascular Science ...
... , This release is available in German . ... beewolves, house beneficial bacteria on their cocoons that guarantee ... Institute for Chemical Ecology in Jena teamed up with ... Leibniz Institute for Natural Product Research Hans-Knoell-Institute - ...
... African-Americans age 65 and younger are more than twice ... any region, and people who have a stroke are more ... researchers at the University of Alabama at Birmingham (UAB) School ... for Geographic and Racial Differences in Stroke (REGARDS) study, one ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: